GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » E10

Adhera Therapeutics (Adhera Therapeutics) E10 : $-35.01 (As of Sep. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Adhera Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was $-0.830. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-35.01 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average E10 Growth Rate was 60.10% per year. During the past 5 years, the average E10 Growth Rate was 61.70% per year. During the past 10 years, the average E10 Growth Rate was 45.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Adhera Therapeutics was 65.90% per year. The lowest was -20.80% per year. And the median was 10.70% per year.

As of today (2024-04-30), Adhera Therapeutics's current stock price is $0.0089. Adhera Therapeutics's E10 for the quarter that ended in Sep. 2023 was $-35.01. Adhera Therapeutics's Shiller PE Ratio of today is .


Adhera Therapeutics E10 Historical Data

The historical data trend for Adhera Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adhera Therapeutics E10 Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,289.19 -545.00 -146.59 -50.95 -34.51

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.67 -34.51 -36.72 -36.19 -35.01

Competitive Comparison of Adhera Therapeutics's E10

For the Biotechnology subindustry, Adhera Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adhera Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's Shiller PE Ratio falls into.



Adhera Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adhera Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.83/129.8595*129.8595
=-0.830

Current CPI (Sep. 2023) = 129.8595.

Adhera Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201312 -22.000 98.326 -29.056
201403 -140.000 99.695 -182.360
201406 22.000 100.560 28.410
201409 -56.000 100.428 -72.412
201412 48.000 99.070 62.918
201503 -8.000 99.621 -10.428
201506 -6.000 100.684 -7.739
201509 -12.000 100.392 -15.522
201512 -4.000 99.792 -5.205
201603 -0.586 100.470 -0.757
201606 -0.600 101.688 -0.766
201609 -0.400 101.861 -0.510
201612 -2.400 101.863 -3.060
201703 -2.400 102.862 -3.030
201706 -2.400 103.349 -3.016
201709 -2.000 104.136 -2.494
201712 -6.000 104.011 -7.491
201803 -2.600 105.290 -3.207
201806 -9.000 106.317 -10.993
201809 -14.600 106.507 -17.801
201812 -6.200 105.998 -7.596
201903 -5.400 107.251 -6.538
201906 -5.800 108.070 -6.969
201909 -5.400 108.329 -6.473
201912 -8.200 108.420 -9.821
202003 -4.000 108.902 -4.770
202006 -2.400 108.767 -2.865
202009 -1.800 109.815 -2.129
202012 -1.600 109.897 -1.891
202103 -2.400 111.754 -2.789
202106 -1.600 114.631 -1.813
202109 -6.380 115.734 -7.159
202112 -2.010 117.630 -2.219
202203 -0.510 121.301 -0.546
202206 -0.270 125.017 -0.280
202209 -0.570 125.227 -0.591
202212 -0.010 125.222 -0.010
202303 -0.290 127.348 -0.296
202306 -0.010 128.729 -0.010
202309 -0.830 129.860 -0.830

Add all the adjusted EPS together and divide 10 will get our e10.


Adhera Therapeutics  (OTCPK:ATRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Adhera Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Adhera Therapeutics (Adhera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.
Executives
Zahed Subhan director 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness director 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: Chief Executive Officer 549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley officer: SVP Finance & Accounting 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan director 812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague officer: Chief Financial Officer C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell director 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato officer: CEO 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris director 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein officer: Chief Legal Officer C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah officer: Chief Financial Officer 10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson officer: Chief Commercial Officer 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif officer: Chief Operating Officer 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679

Adhera Therapeutics (Adhera Therapeutics) Headlines

From GuruFocus

Marina Biotech Appoints Nancy R. Phelan to the Board of Directors

By Marketwired Marketwired 10-03-2018

MDRNA Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-15-2010